New Products In Brief
This article was originally published in The Gray Sheet
Executive Summary
CryoLife CryoPatch SG: Cardiac patch gains 510(k) clearance for repair or reconstruction of the right ventricular outflow tract, announced Aug. 12. Processed with CryoLife's proprietary SynerGraft technology, the human collagen matrix device addresses a niche U.S. market worth about $15 million, according to the company. Right ventricular outflow tract repair or reconstruction is commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus and Pulmonary Atresia. The device is available in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk and pulmonary branch. Shipments will start by the end of September, CryoLife says
You may also be interested in...
Kinetic Concepts' Five-Year Plan Centers On New Products, Market Expansion
Kinetic Concepts aims to grow annual revenues at a rate of 6%-8% over the next five years by expanding its negative pressure wound therapy product offerings, expanding further beyond NPWT devices and entering new geographic markets, the company said during its Nov. 9 analyst day in New York
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.